Search Results
Aug 05, 2026, 10:00 ET Altruist Biologics Completes First Commercial PPQ Campaign of its 20,000L Production Line at the Hangzhou Site
2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), announced the successful completion of the first commercial project Process Performance Qualification (PPQ) campaign for its 20,000L stainless steel
More news about: Altruist Biologics
Aug 05, 2026, 10:00 ET Altruist Biologics Completes First Commercial PPQ Campaign of its 20,000L Production Line at the Hangzhou Site
2026 /PRNewswire/ -- Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), announced the successful completion of the first commercial project Process Performance Qualification (PPQ) campaign for its 20,000L stainless steel
More news about: Altruist Biologics
Aug 05, 2026, 08:00 ET Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
mandatory legal requirement for entities operating in the contract development and manufacturing organization (CDMO) model.Porton Advanced has established comprehensive CRO and CDMO platforms covering plasmids, viral vectors, cell therapy, gene therapy, nucleic acid therapeutics, and exosome.
More news about: Porton Advanced
Aug 05, 2026, 07:31 ET Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
manufacturing as a CDMO partner.About Porton AdvancedPorton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has dual-headquarters in Cranbury, New Jersey, and Suzhou, China, providing end-to-end CDMO solutions
More news about: Porton Advanced
Aug 05, 2026, 04:24 ET Piramal Pharma Solutions amplia il proprio stabilimento per API peptidici con una suite avanzata di essiccazione a spruzzo
agosto 2026 /PRNewswire/ --Piramal Pharma Solutions ("PPS"), una delle principali organizzazioni mondiali di sviluppo e produzione a contratto (CDMO), parte di Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), ha avviato una suite di essiccazione a spruzzo all'avanguardia presso il suo stabilimento
More news about: Piramal Pharma Solutions
Aug 05, 2026, 02:06 ET Piramal Pharma Solutions erweitert Peptid-API-Anlage um moderne Sprühtrocknungsanlage
5. August 2026 /PRNewswire/ -- Piramal Pharma Solutions („PPS"), ein weltweit führendes Auftragsentwicklungs- und Produktionsunternehmen (CDMO) und Teil der Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) hat in seiner Spezialanlage für die Entwicklung und Herstellung von Peptiden in Turbhe,
More news about: Piramal Pharma Solutions
Aug 04, 2026, 23:05 ET Piramal Pharma Solutions agrandit son site de production d'API peptidiques avec l'ajout d'une unité de séchage par atomisation de pointe
/PRNewswire/ -- Piramal Pharma Solutions (« PPS »), l'un des principaux acteurs mondiaux du secteur du développement et de la fabrication sous contrat (CDMO) et filiale de Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) a mis en service une unité de séchage par atomisation à la pointe de la technologie
More news about: Piramal Pharma Solutions
Aug 04, 2026, 18:44 ET Piramal Pharma Solutions amplía sus instalaciones de producción de principios activos peptídicos
de agosto de 2026 /PRNewswire/ -- Piramal Pharma Solutions ("PPS"), una organización líder mundial en desarrollo y fabricación por contrato (CDMO) y parte de Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), ha inaugurado una moderna planta de secado por pulverización en sus instalaciones dedicadas
More news about: Piramal Pharma Solutions
Aug 04, 2026, 08:30 ET AsymBio Secures US$184 Million Capital Injection to Support Long-Term Growth
AsymBio and the biologics CDMO sector. Hillhouse has a long track record of investing across the biopharmaceutical value chain and the broader global healthcare sector. Its investment aligns with Asymchem Group's differentiated, one-stop, end-to-end CDMO strategy.Globally,
More news about: AsymBio
Aug 04, 2026, 05:08 ET Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
Aug. 4, 2026 /PRNewswire/ -- Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has launched a state-of-the-art spray drying suite at its dedicated peptide development
More news about: Piramal Pharma Solutions
Aug 04, 2026, 04:51 ET Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
Aug. 4, 2026 /PRNewswire/ -- Piramal Pharma Solutions ("PPS"), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), has launched a state-of-the-art spray drying suite at its dedicated peptide development
More news about: Piramal Pharma Solutions
Aug 03, 2026, 12:16 ET Codis Completes Acquisition of Catalent's Nottingham, UK Facility, Expanding Europe's Premier Spray Dry Network
England, Aug. 3, 2026 /PRNewswire/ -- Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering solutions, today announced the successful closing
More news about: Codis
Aug 03, 2026, 12:12 ET Codis Completes Acquisition of Catalent's Nottingham, UK Facility, Expanding Europe's Premier Spray Dry Network
England, Aug. 3, 2026 /PRNewswire/ -- Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering solutions, today announced the successful closing
More news about: Codis
Aug 03, 2026, 08:17 ET Genezen and the Raiden Science Foundation Announce Partnership for AAV9 Gene Replacement Therapy for UBA5 Clinical Trial
Aug. 3, 2026 /PRNewswire/ -- Genezen, a best-in-class gene therapy contract development and manufacturing organization (CDMO), and the Raiden Science Foundation (RSF), a parent-led rare disease organization, today announced a manufacturing partnership for an AAV Serotype 9
More news about: Genezen
Jul 31, 2026, 08:00 ET Quasar Medical Acquires Nitinol Design and Development Center
DIEGO, July 31, 2026 /PRNewswire/ -- Quasar Medical, a global contract development and manufacturing organization (CDMO) specializing in minimally invasive medical devices, announced the acquisition of the Medres' Nitinol Design and Development Center in San Diego,
More news about: Quasar Medical
Jul 30, 2026, 12:33 ET Piramal Pharma Limited annuncia i risultati del primo trimestre dell'anno fiscale 2027
17 % CDMO1.187
More news about: Piramal Pharma Limited
Jul 30, 2026, 10:31 ET Piramal Pharma Limited annonce ses résultats pour le T1 2027
17 % CDMO1 187
More news about: Piramal Pharma Limited
Jul 30, 2026, 10:30 ET Laboratory Freezers Market worth $5.11 billion by 2031 - Exclusive Report by MarketsandMarkets™
Exclusion, Reverse and Normal Phases, HPLC, Affinity, Chiral), Capacity (1-100 ml, 100-1000 ml, >1 liter), End User (Pharma & Biotech, CRO, CDMO) - Global Forecast to 2031
More news about: MarketsandMarkets
Jul 30, 2026, 07:02 ET Piramal Pharma Limited、27年度第1四半期の業績を発表
17 % CDMO1,187
More news about: Piramal Pharma Limited
Jul 30, 2026, 06:39 ET Piramal Pharma Limited gibt die Ergebnisse für das erste Quartal des Geschäftsjahres 2027 bekannt
17 % CDMO1,187
More news about: Piramal Pharma Limited
Jul 30, 2026, 04:27 ET Piramal Pharma Limited anuncia sus resultados para el primer trimestre del año fiscal 2027
17 % CDMO1.187
More news about: Piramal Pharma Limited
Jul 29, 2026, 15:38 ET Piramal Pharma Limited Announces Results for Q1 FY27
17 % CDMO1,187
More news about: Piramal Pharma Limited
Jul 29, 2026, 15:27 ET Piramal Pharma Limited Announces Results for Q1 FY27
17 % CDMO1,187
More news about: Piramal Pharma Limited
Jul 29, 2026, 13:14 ET GMP Biologics Market to Reach US$98.2 Bn by 2033 Accelerates with Biopharmaceutical Innovation - Persistence Market Research
countries.South Korea continues strengthening its leadership through Samsung Biologics' world-scale manufacturing campus, while China is expanding global CDMO capabilities through companies such as WuXi Biologics. India is rapidly increasing biologics manufacturing capacity through its strong biosimilar industry
More news about: Persistence Market Research Pvt. Ltd.
Jul 29, 2026, 08:30 ET Improve Biologic Modalities Manufacturing for mAb Readiness, Upcoming Webinar Hosted by Xtalks
characterization and common approaches such as Protein A chromatography. Attendees will also explore how process robustness, scale-up planning and experienced CDMO support can help prepare mAb programs for clinical and commercial manufacturing.TORONTO, July
More news about: Xtalks